国产成人精品日本亚洲999,99久久久国产精品免费蜜臀 ,v一区无码内射国产,被调教的少妇雅芳1一19,国产成人a亚洲精v品无码

更新于 2025-08-30 01:53:51

CADD/AIDD研究員 (MJ013465)

2.3-3萬(wàn)·14薪
  • 上海閔行區(qū)
  • 經(jīng)驗(yàn)不限
  • 博士
  • 全職
  • 招1人

雇員點(diǎn)評(píng)標(biāo)簽

  • 工作環(huán)境好
  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 氛圍活躍
  • 人際關(guān)系好
  • 交通便利
  • 非常鍛煉人
  • 能學(xué)到東西

職位描述

MOE
We have an open position in the Department of Molecular Informatics at Shanghai Hengrui
Pharmaceutical Co., Ltd. This person will actively provide CADD and/or AIDD support
for small molecule drug discovery projects at different stages independently or
under limited supervision. In addition, he/she should be an active contributor
to the advancement of the key technologies within the organization, and share
computational expertise within the organization.

Requirements:

1. PhD degree in chemistry, pharmacy, life sciences or computational sciences with a
proven track record in CADD and/or AIDD; experienced MS level scientists are
also welcomed to apply.
2. Ideal candidates should have expertise in at least one of the following fields: chem/bioinformatics,
QSAR, structure-based drug design, molecular modeling, ADMET modeling, as well
as machine learning.
3. Experience in applying molecular modeling software (e.g. Schr?dinger, MOE) and
cheminformatics approaches in lead discovery and optimization to support
various drug discovery projects.
4. Previous scientific programming experience is required; proficiency in Python, R or SVL
is highly preferred.
5. Training and in-depth knowledge in synthetic medicinal chemistry and pharmacology are
highly desirable.
6. The ability to work effectively within a multi-discipline environment is essential.
7. Good verbal and written communication skills, and fluent in Chinese and English.
8. Fast learner, team player, creative thinker and passionate about drug discovery and
life sciences.

工作地點(diǎn)

閔行區(qū)上海恒瑞醫(yī)藥有限公司

職位發(fā)布者

邱菲/HRBP

昨日活躍
立即溝通
公司Logo江蘇恒瑞醫(yī)藥股份有限公司公司標(biāo)簽
恒瑞醫(yī)藥(股票代碼:600276.SH,01276.HK)創(chuàng)立于1970年,是一家專注研發(fā)、生產(chǎn)及推廣高品質(zhì)藥物的創(chuàng)新型國(guó)際化制藥企業(yè),聚焦腫瘤、代謝和心血管疾病、免疫和呼吸系統(tǒng)疾病以及神經(jīng)科學(xué)等領(lǐng)域進(jìn)行新藥研發(fā),是國(guó)內(nèi)最具創(chuàng)新能力的制藥龍頭企業(yè)之一。五十余年來,恒瑞醫(yī)藥始終堅(jiān)持為患者服務(wù)的初心,努力守護(hù)患者健康生活和生命質(zhì)量,攻堅(jiān)克難推進(jìn)醫(yī)藥產(chǎn)業(yè)高質(zhì)量發(fā)展。在美國(guó)制藥經(jīng)理人雜志公布的全球制藥企業(yè)TOP50榜單中,恒瑞醫(yī)藥已連續(xù)6年上榜;國(guó)際知名咨詢機(jī)構(gòu)Citeline發(fā)布的全球TOP25管線規(guī)模制藥公司榜單,恒瑞醫(yī)藥連續(xù)4年上榜,2025年自研管線數(shù)量位居全球第二;中國(guó)醫(yī)藥工業(yè)信息中心歷年發(fā)布的“中國(guó)醫(yī)藥研發(fā)產(chǎn)品線最佳工業(yè)企業(yè)”,恒瑞醫(yī)藥已12次登頂榜首。
公司主頁(yè)